Primary sclerosing cholangitis - an insidious enemy of the liver - case report
DOI:
https://doi.org/10.12775/JEHS.2022.12.09.096Keywords
cirrhosis, cholestasis, ultrasonographyAbstract
Background and introduction
Primary sclerosing cholangitis (PSC) is a chronic liver disease with features of cholestasis as a result of inflammation and damage to the bile ducts, which can eventually lead to liver fibrosis and parenchymal failure at an advanced stage.
Case Report
A 22-year-old man was admitted urgently to the Department of Gastroenterology for complaints of abdominal pain, weakness and tarry stools. A panel of detailed examinations was performed to establish the diagnosis. An abdominal ultrasound scan showed significant enlargement of the liver and spleen. Gastroscopy revealed variceal columns of II degree in the lower esophagus, which were cauterized. Laboratory tests confirmed anemia, reduced platelet and white blood cell counts, increased activity of ALT, ASP, GTP, ALP and slight elevation of total bilirubin in the blood. Based on the clinical disease manifestation and the results of diagnostic tests, cirrhosis of unknown origin was suspected. Subsequent magnetic resonance cholangiopancreatography (MRCP) revealed the presence of multiple strictures in the intra- and extrahepatic bile ducts and gave rise to the diagnosis of PSC. Pharmacological treatment was administered. Currently, the patient remains under the close care of the Transplant Clinic, where he undergoes regular checks of liver function, and endoscopic variceal ligation (EVL) as required.
Discussion with conclusions
The case presented here shows that the course of PSC can be insidious and asymptomatic. Despite the absence of clinical symptoms, the disease can lead to the development of advanced cirrhosis even in patients of young age and be diagnosed as late as at the decompensated stage, when the only treatment option remains organ transplantation.
References
Fricker ZP, Lichtenstein DR. Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management. Digestive Diseases and Sciences 2019 64 632–642. https://doi.org/10.1007/s10620-019-05484-y
Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut 2019 68 1356-1378. https://doi:10.1136/gutjnl-2018-317993
Walczyk J, Walas MK. Standards of the Polish Ultrasound Society - update. Spleen examination. Journal of Ultrasonography 2013 13 50-64. https://doi.org/10.15557%2FJoU.2013.0004
Akanni D, Alassan K, Kiki M, Djohoun B, Tove K, Sehonou J. Ultrasound Diameter of the Portal Vein to Healthy Adult in Parakou (Benin). Open Journal of Medical Imaging 2021 11 145-152. https://doi.org/10.4236/ojmi.2021.114013
Prokopič M, Beuers U. Management of primary sclerosing cholangitis and its complications: an algorithmic approach. Hepatology International 2021 15 6-20. https://doi.org/10.1007/s12072-020-10118-x
Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. The Lancet 2018 391 2547-2559. https://doi.org/10.1016/S0140-6736(18)30300-3
Fujisawa T, Ushio M, Takahashi S, Yamagata W, Takasaki Y, Suzuki A, Okawa Y, Ochiai K, Tomishima K, Ishii S, Saito H, Isayama H. Role of Peroral Cholangioscopy in the Diagnosis of Primary Sclerosing Cholangitis. Diagnostics 2020 10 268. https://doi.org/10.3390/diagnostics10050268
Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. Journal of Hepatology 2017 67 1298-1323. https://doi.org/10.1016/j.jhep.2017.07.022
de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World Journal of Gastroenterology 2015 21 1956-1971.https://doi.org/10.3748%2Fwjg.v21.i6.1956
Sano H, Nakazawa T, Ando T, Hayashi K, Naitoh I, Okumura F, Miyabe K, Yoshida M, Takahashi S, Ohara H, Joh T. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. Journal of Hepatobiliary Pancreatic Science 2011 18 154-161. https://doi.org/10.1007/s00534-010-0319-8
Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz SH. Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features. Gut and Liver 2018 12 17-29. https://doi.org/10.5009%2Fgnl16510
Gulamhusein AF, Eaton JE, Tabibian JH, Atkinson EJ, Juran BD, Lazaridis KN. Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD. The American Journal of Gastroenterology 2016 111 705-711. https://doi.org/10.1038%2Fajg.2016.55
Ngu JH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clinical Gastroenterology and Hepatology 2011 9 1092-1097. https://doi.org/10.1016/j.cgh.2011.08.027
Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson A, Lindgren S, Prytz H, Hultcrantz R, Lööf LA, Sandberg-Gertzén H, Almer S, Askling J, Ehlin A, Ekbom A. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clinical Gastroenterology and Hepatology 2008 6 939-943. https://doi.org/10.1016/j.cgh.2008.03.016
Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, Lie BA, Bergquist A, Schramm C, Weismüller TJ, Gotthardt D, Rust C, Philipp EE, Fritz T, Henckaerts L, Weersma RK, Stokkers P, Ponsioen CY, Wijmenga C, Sterneck M, Nothnagel M, Hampe J, Teufel A, Runz H, Rosenstiel P, Stiehl A, Vermeire S, Beuers U, Manns MP, Schrumpf E, Boberg KM, Schreiber S. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010 138 1102-1111. https://doi.org/10.1053/j.gastro.2009.11.046
Andersen IM, Tengesdal G, Lie BA, Boberg KM, Karlsen TH, Hov JR. Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis. Clinical Gastroenterology and Hepatology 2014 12 1019-1028. https://doi.org/10.1016/j.cgh.2013.09.024
Eaton JE, Juran BD, Atkinson EJ, Schlicht EM, Xie X, de Andrade M, Lammert CS, Luketic VA, Odin JA, Koteish AA, Kowdley KV, Chopra KB, Hirschfield GM, Chalasani NP, Lazaridis KN. A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2015 41 980-90. https://doi.org/10.1111%2Fapt.13154
Little R, Wine E, Kamath BM, Griffiths AM, Ricciuto A. Gut microbiome in primary sclerosing cholangitis: A review. World Journal of Gastroenterology 2020 26 2768-2780. https://doi.org/10.3748%2Fwjg.v26.i21.2768
Lemoinne S, Kemgang A, Ben Belkacem K, Straube M, Jegou S, Corpechot C; Saint-Antoine IBD Network, Chazouillères O, Housset C, Sokol H. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut 2020 69 92-102. https://doi.org/10.1136/gutjnl-2018-317791
Peerani F, Du L, Lytvyak E, Bain VG, Mason AL, Bailey RJ, Montano-Loza AJ. Serum IgG4 cut-off of 70 mg/dL is associated with a shorter time to cirrhosis decompensation and liver transplantation in primary sclerosing cholangitis patients. Canadian Liver Journal 2022 5 31-42. https://doi.org/10.3138%2Fcanlivj-2021-0023
Floreani A, De Martin S. Treatment of primary sclerosing cholangitis. Digestive and Liver Disease 2021 53 1531-1538. https://doi.org/10.1016/j.dld.2021.04.028
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Kinga Knop, Zuzanna Piasecka, Anna Kochanowska, Aneta Glaz, Ewelina Wesolek, Beata Kasztelan-Szczerbinska, Barbara Skrzydlo-Radomanska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 474
Number of citations: 0